The condition that had no cure was cured.
For generations, pre-eclampsia has confronted pregnant people with a condition medicine could only soften, never resolve — a dangerous rise in blood pressure that threatens both mother and child, ending too often in stillbirth or premature delivery. Now, researchers at the University of Pennsylvania have done what once seemed beyond reach: using the lipid nanoparticle technology refined during the COVID-19 vaccine era, doctoral student Kelsey Swingle and her team have delivered an mRNA therapy directly to the placenta, normalizing blood pressure and improving fetal health in pregnant mice. It is, in the long arc of reproductive medicine, the first genuine candidate for a cure — and a reminder that foundational, unglamorous scientific work can quietly change everything.
- Pre-eclampsia strikes 3–5% of pregnancies worldwide with no cure in sight — only symptom management, bed rest, and the grim calculus of early delivery.
- Kelsey Swingle built her research from the ground up, mastering mouse placental anatomy and pre-eclampsia models that barely existed in the literature before she arrived.
- After screening 98 lipid nanoparticle formulations, one emerged that delivered mRNA to the placenta 100 times more effectively than the current FDA-approved standard.
- A single injection in pre-eclamptic mice lowered maternal blood pressure through delivery, improved fetal circulation, and produced heavier, healthier pups at birth.
- The path to human trials runs through larger animals — rats, then guinea pigs with human-like placentas — while the team explores a spin-off company to carry the therapy toward clinical use.
Pre-eclampsia offers pregnant people no real choices: manage the blood pressure, stay in bed, or deliver early and hope. It touches three to five percent of pregnancies globally and remains a leading driver of stillbirth and prematurity. For decades, medicine has had nothing to actually fix it.
Kelsey Swingle, a doctoral student in Michael Mitchell's bioengineering lab at the University of Pennsylvania, decided to ask a different question. The lipid nanoparticle technology that carried mRNA into cells during the COVID-19 vaccine rollout had proven it could reach specific tissues with precision — so why not the placenta? Swingle had to construct the scientific foundation herself, learning mouse placental anatomy from scratch and developing pre-eclampsia models that barely existed in the literature.
From there, she screened 98 different lipid nanoparticle formulations. One outperformed all others by a factor of more than 100 compared to the FDA-approved alternative. Injected on day 11 of a 20-day mouse gestation, it brought maternal blood pressure down and kept it there through delivery, improved fetal blood circulation, and produced heavier litters — a reliable marker of health for both mother and offspring. The findings were published in Nature.
Mice, of course, are not humans. The team's next steps move through rats and then guinea pigs, whose placentas more closely mirror our own, before any human trials could begin. Swingle and Mitchell are already discussing a spin-off company to guide the therapy toward clinical development. For the millions of pregnant people who have faced pre-eclampsia with no real options, the existence of a path forward is itself something new.
Pre-eclampsia arrives without warning and without cure. A pregnant person's blood pressure climbs. Blood flow to the placenta falters. The fetus starves for oxygen. The mother faces organ damage, seizure, death. The only option medicine has offered for decades is to wait, manage symptoms with pills, stay in bed, or deliver the baby early—sometimes fatally early—and hope. This happens to three to five percent of all pregnancies worldwide. It is one of the leading causes of stillbirth and prematurity on the planet. And until now, there has been nothing to actually fix it.
Kelsey Swingle, a doctoral student at the University of Pennsylvania's bioengineering lab, decided that wasn't good enough. Working under Associate Professor Michael Mitchell, she began asking a different question: what if you could deliver a therapeutic directly to the placenta itself, using the same lipid nanoparticle technology that carried mRNA into cells during the COVID vaccine rollout? What if you could engineer a cure?
Swingle started from nothing. The scientific literature on mRNA therapies in pregnant mice was sparse. Studies on pre-eclamptic mice barely existed. She had to learn mouse placental anatomy from scratch, figure out how to induce pre-eclampsia in rodents in a way that actually mimicked the human disease, and track gestational days instead of weeks to know precisely where each pregnancy stood. It was foundational work that most researchers would have skipped. She did not.
Once the groundwork was laid, Swingle screened 98 different lipid nanoparticle formulations, testing each one's ability to reach the placenta and reduce blood pressure in pre-eclamptic pregnant mice. One formulation stood out. It delivered mRNA to the placenta more than 100 times more effectively than the FDA-approved lipid nanoparticle already in use. A single injection on day 11 of a 20-day mouse gestation—given to mice with induced pre-eclampsia—worked. Maternal blood pressure dropped and stayed down through delivery. Fetal blood circulation improved. At birth, the pups weighed more, a sign of maternal and fetal health. The condition that had no cure was cured.
"Our LNP was able to deliver an mRNA therapeutic that reduced maternal blood pressure through the end of gestation and improved fetal health and blood circulation in the placenta," Swingle said. "Additionally, at birth we saw an increase in litter weight of the pups, which indicates a healthy mom and healthy babies." The work was published in Nature.
But mice are not humans. The next phase requires testing in larger animals—rats first, then guinea pigs, whose placentas more closely resemble human ones and whose pregnancies last up to 72 days. The team needs to know how many doses a larger animal would require, whether the minimum effective dose would change, and whether the therapy would work as well in a more complex biological system. Only after those studies could human trials begin.
Swingle and Mitchell are already in conversation about launching a spin-off company to shepherd the therapy toward clinical development and eventual market approval. There is more research ahead—optimizing the nanoparticle further, understanding the precise mechanisms by which it reaches the placenta, exploring whether the same approach could treat other reproductive health conditions that currently have no cure. But for the first time, there is a path forward. For the millions of pregnant people who face pre-eclampsia with no real options, that path matters.
Citas Notables
Our LNP was able to deliver an mRNA therapeutic that reduced maternal blood pressure through the end of gestation and improved fetal health and blood circulation in the placenta. Additionally, at birth we saw an increase in litter weight of the pups, which indicates a healthy mom and healthy babies.— Kelsey Swingle, doctoral student
Over the last few years, Kelsey has enthusiastically helped grow and lead a team of engineers in my lab who are passionate about women's health. She truly understands the importance of a strong and supportive scientific community to execute cutting-edge research.— Michael Mitchell, Associate Professor in Bioengineering
La Conversación del Hearth Otra perspectiva de la historia
Why does pre-eclampsia matter so much as a research problem? It sounds serious, but three to five percent—is that really a crisis?
Three to five percent of all pregnancies globally is roughly 5 to 8 million cases a year. It's the leading cause of stillbirth and prematurity worldwide. That's not a small number. And the people affected have almost no good choices—manage symptoms, stay in bed, or deliver a baby who may not survive outside the womb. There's no cure.
So Swingle had to build the entire research foundation from scratch. Why was so little known about mRNA in pregnant mice?
Pregnancy research is complicated and expensive. You can't just use standard protocols. You have to learn the anatomy, track gestational days instead of weeks, induce disease in a way that actually mirrors what happens in humans. Most researchers avoid it. Swingle didn't.
The lipid nanoparticles—those are the same delivery vehicles from the COVID vaccine, right?
Exactly. But Swingle had to find the right formulation for the placenta specifically. She tested 98 different ones. The winner delivered mRNA over 100 times more effectively than what the FDA had already approved. That's not incremental improvement. That's a breakthrough.
And it worked in the mice. One injection, and the disease was cured?
One injection on day 11 of a 20-day pregnancy. Blood pressure dropped and stayed down. Fetal circulation improved. The pups were heavier at birth. But mice aren't humans, so now she has to test in larger animals before any human trials.
What comes next for her?
Guinea pigs, probably. Their placentas look like human ones, and their pregnancies last longer. Then rats. Then, if it works, human trials. And she's already talking about starting a company to move this toward the clinic. This isn't just a paper anymore. It's becoming a real drug.